ADHD drug gets three more dosage strengths

Article

Shire's ADHD treatment lisdexamfetamine (Vyvanse) was approved by the FDA in three new dosage strengths. The current 30 mg-, 50 mg and 70 mg-dosage strengths will be joined by 20 mg-, 40 mg-, and 60 mg-dosage strengths. They will be available in the second quarter of this year.

Lisdexamfetamine is approved to treat ADHD in children between 6 and 12 years of age. Many who receive treatment have their dose levels titrated up or down. These additional dosage strengths could offer a more gradual process in titrating, 10 mg at a time.

Newsletter

Access practical, evidence-based guidance to support better care for our youngest patients. Join our email list for the latest clinical updates.

Subscribe Now!
Recent Videos
Discussing phase 3 data of Panzyga for PANS, with Michael Daines, MD
Peter S. Jensen, MD
Rakesh Jain, MD, MPH
Rakesh Jain, MD, MPH
Alan Percy, MD
Alan Percy, MD
Perry Roy, MD
Perry Roy, MD | Image Credit: Carolina Attention Specialists
Related Content
Social media exposure tied to adolescent cannabis and dual substance use | Image Credit: © New Africa - stock.adobe.com.

Social media exposure linked to increased cannabis, dual substance use in adolescents

Morgan Ebert, Managing Editor
June 24th 2025
Article

Frequent exposure to cannabis and e-cigarette posts on social media is linked to increased teen cannabis and dual substance use, according to a study published in JAMA.

ADHD Medications: A Look at Their Safety Profile

ADHD Medications: A Look at Their Safety Profile

Joan Daughton, MD
October 17th 2012
Podcast

Each year in this country, physicians prescribe medications to treat ADHD in nearly 3 million children. The safety of these agents has been the subject of some debate.

Artificial intelligence improves accuracy in estimating child abuse | Image Credit: © mihakonceptcorn - stock.adobe.com.

Artificial intelligence improves accuracy in estimating child abuse

Morgan Ebert, Managing Editor
April 27th 2025
Article

New model refines prevalence estimates, reduces misdiagnoses compared to the current coding system.

Image Credit: © EKKAPON - stock.adobe.com.

CBD may ease autism symptoms in children

Morgan Ebert, Managing Editor
April 9th 2025
Article

CBD cannabis extract may improve social responsiveness and reduce disruptive behavior in children with autism, with no increase in adverse effects, according to a recent study

Pediatric FDA, clinical trial, and interview recap from Q1 2025 | Image Credit: © Araki Illustrations - © Araki Illustrations - stock.adobe.com.

Q1 2025: A recap of the top headlines and interviews

Joshua Fitch, Senior Editor ;Morgan Ebert, Managing Editor
April 3rd 2025
Article

View our Q1 2025 recap of standout pediatric news from FDA regulatory updates, clinical trial results, and expert commentary.

Cingulate reports phase 3 safety data for CTx-1301 to treat ADHD in children, adolescentsLatest revision | Image Credit: © Stepan Popov - © Stepan Popov - stock.adobe.com.

Cingulate reports phase 3 safety data for CTx-1301 to treat ADHD in children, adolescents

Joshua Fitch, Senior Editor
March 4th 2025
Article

Results will be included an a final analysis of safety and efficacy data for CTx-1301, which will be included in a NDA submission with the FDA, stated Cingulate Inc.

© 2025 MJH Life Sciences

All rights reserved.